Preliminary analysis on the establishment of drug innovation system and the innovation progress of Chinese pharmaceutical enterprises_West China Medical Journal

Authors：

CHAI Huiting ¹ , LIU Zhenming ² ,  WANG Zhifeng ¹

1. School of Public Health, Peking University, Beijing 100191, P. R. China;
2. State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, P. R. China;

Corresponding author：

WANG Zhifeng, Email: zhfwangwf@163.com

Keywords：

National drug innovation system; Pharmaceutical enterprises innovation; The location of pharmaceutical enterprises; The Drug Innovation Major Project

DOI：

10.7507/1002-0179.201801164

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

The pharmaceutical industry is characterized by the intensive capital and knowledge. Its international competitiveness and sustainable development should be established on a complete national drug innovation system. At the same time, the development of new drug innovation system in China can be really promoted by the accurate location of pharmaceutical enterprises as research and development (R & D) and production, the improved R & D strength, as well as the increased investment in innovation. This paper reviews both the development of Chinese drug innovation system and the orientation of pharmaceutical enterprises innovation during this process. Furthermore, the changes of innovation capability and positioning of pharmaceutical companies have been investigated before and after the launch of the Drug Innovation Major Project. Although, the construction of Chinese pharmaceutical innovation system has greatly promoted the progress of our pharmaceutical companies, a wide gap in the level of drug innovation still exists between Chinese pharmaceutical enterprises and international leading drug companies in the world.

Citation： CHAI Huiting, LIU Zhenming, WANG Zhifeng. Preliminary analysis on the establishment of drug innovation system and the innovation progress of Chinese pharmaceutical enterprises. West China Medical Journal, 2018, 33(3): 359-363. doi: 10.7507/1002-0179.201801164 Copy

1.	李震静, 马颖, 刘瑛, 等. 我国卫生行业协同创新研究的描述性系统评价. 中国卫生事业管理, 2017(6): 477-480.
2.	Organisation for Economic Co-operation and Development (OECD). National innovation system. Paris: OECD, 1997: 9-10.
3.	蒋毅, 毕开顺. 国际新药创新体系比较及对中国的启示. 科学学与科学技术管理, 2010, 31(2): 40-45.
4.	吴珩, 郑玉果, 陈颖, 等. 从重大新药创制专项" 十一五”计划探索我国新药创制研发网络的构建及基本特征. 中国新药杂志, 2014, 23(21): 2465-2469.
5.	汪家宝. 中国医药产业可持续发展路径研究. 南京财经大学学报, 2014(3): 34-38.
6.	罗文华, 孙利华, 周静. 中国医药产业结构高级化评价. 中国新药杂志, 2016, 25(14): 1566-1571.
7.	李红梅. 美国: 健康产业成" 老大” 医院以私立医院为主. 人民日报, 2015-01-19(17).
8.	杨子来, 袁景亮, 尹明杰, 等. 我国医学科技创新成果孵化器的现状分析. 卫生软科学, 2016, 30(6): 48-50.
9.	闭明雄. 科技成果市场化中的产权问题及模式选择. 科技创新与生产力, 2017(7): 1-6.
10.	曹阳, 周晓夏. 制药业创新成果转化效率及影响因素实证分析. 中国医药工业杂志, 2016, 47(2): 246-249.
11.	蒋晓萌. 国外制药企业新药研发模式及分析比较. 经济研究导刊, 2012, 169(23): 36-38.
12.	郑海涛. 生物医药产业的创新链模式研究. 科技进步与对策, 2003, 20(7): 113-115.
13.	生意社. 构建可持续发展的中国医药创新生态系统. 中国医药报, 2016-11-25(1).
14.	陈凯先. 创新药物研发进入革命性变化时代——努力从医药制造大国向医药创新强国转变. 人民日报, 2016-10-30(5).
15.	白宇. 把人民健康放在优先发展战略地位, 努力全方位全周期保障人民健康-习近平在全国卫生健康大会上的讲话. 人民日报, 2016-08-21(1).
16.	谭嘉. 把科技创新放在核心位置. 健康报, 2016-10-17(1).
17.	The European Federation of Pharmaceutical Industries and Associations. The pharmaceutical industry in figures. (2014-12-06)[2017-12-20] . http://www.efpia.eu/uploads/Figures_ 2014_Final.pdf.
18.	中华人民共和国国务院. 国家中长期科学和技术发展规划纲要(2006-2020年). (2006-02-06)[2017-12-30] . http://www. gov.cn/gongbao/content/2006/content_240244.htm.
19.	CubeX. Global pharmaceutical market outlook: 2015. (2013-02-23)[2017-12-20]. http://cubex.co.in/PDF/Global_ Pharmaceutical_Market.pdf.
20.	胡芳. 医药研发决战未来十年-四大行业组织发布中国医药创新生态系统报告. 中国医药报, 2016-11-23(A08).
21.	健康报评论员. 用科技创新支撑健康中国. 健康报, 2016-10-17(1).
22.	刘子晨,梁振. 2016竞争力: 医药上市公司研发投入10强榜. (2016-09-04)[2017-12-20] . http://www.phirda.com/newsinfo. aspx?id=15779.
23.	王蔚佳. 重大新药创制科技专项正式启动. 中国医药报, 2008-08-23(1).
24.	孙宇, 米献淼, 李鹏燕, 等. " 重大新药创制”重大专项: 中国药物创新体系建设与发展的新引擎. 中国新药杂志, 2013, 22(8): 868-872.
25.	Lanthier M, Miller KL, Nardinelli C, et al. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011. Health Aff (Millwood), 2013, 32(8): 1433-1439.

1. 李震静, 马颖, 刘瑛, 等. 我国卫生行业协同创新研究的描述性系统评价. 中国卫生事业管理, 2017(6): 477-480.
2. Organisation for Economic Co-operation and Development (OECD). National innovation system. Paris: OECD, 1997: 9-10.
3. 蒋毅, 毕开顺. 国际新药创新体系比较及对中国的启示. 科学学与科学技术管理, 2010, 31(2): 40-45.
4. 吴珩, 郑玉果, 陈颖, 等. 从重大新药创制专项" 十一五”计划探索我国新药创制研发网络的构建及基本特征. 中国新药杂志, 2014, 23(21): 2465-2469.
5. 汪家宝. 中国医药产业可持续发展路径研究. 南京财经大学学报, 2014(3): 34-38.
6. 罗文华, 孙利华, 周静. 中国医药产业结构高级化评价. 中国新药杂志, 2016, 25(14): 1566-1571.
7. 李红梅. 美国: 健康产业成" 老大” 医院以私立医院为主. 人民日报, 2015-01-19(17).
8. 杨子来, 袁景亮, 尹明杰, 等. 我国医学科技创新成果孵化器的现状分析. 卫生软科学, 2016, 30(6): 48-50.
9. 闭明雄. 科技成果市场化中的产权问题及模式选择. 科技创新与生产力, 2017(7): 1-6.
10. 曹阳, 周晓夏. 制药业创新成果转化效率及影响因素实证分析. 中国医药工业杂志, 2016, 47(2): 246-249.
11. 蒋晓萌. 国外制药企业新药研发模式及分析比较. 经济研究导刊, 2012, 169(23): 36-38.
12. 郑海涛. 生物医药产业的创新链模式研究. 科技进步与对策, 2003, 20(7): 113-115.
13. 生意社. 构建可持续发展的中国医药创新生态系统. 中国医药报, 2016-11-25(1).
14. 陈凯先. 创新药物研发进入革命性变化时代——努力从医药制造大国向医药创新强国转变. 人民日报, 2016-10-30(5).
15. 白宇. 把人民健康放在优先发展战略地位, 努力全方位全周期保障人民健康-习近平在全国卫生健康大会上的讲话. 人民日报, 2016-08-21(1).
16. 谭嘉. 把科技创新放在核心位置. 健康报, 2016-10-17(1).
17. The European Federation of Pharmaceutical Industries and Associations. The pharmaceutical industry in figures. (2014-12-06)[2017-12-20] . http://www.efpia.eu/uploads/Figures_ 2014_Final.pdf.
18. 中华人民共和国国务院. 国家中长期科学和技术发展规划纲要(2006-2020年). (2006-02-06)[2017-12-30] . http://www. gov.cn/gongbao/content/2006/content_240244.htm.
19. CubeX. Global pharmaceutical market outlook: 2015. (2013-02-23)[2017-12-20]. http://cubex.co.in/PDF/Global_ Pharmaceutical_Market.pdf.
20. 胡芳. 医药研发决战未来十年-四大行业组织发布中国医药创新生态系统报告. 中国医药报, 2016-11-23(A08).
21. 健康报评论员. 用科技创新支撑健康中国. 健康报, 2016-10-17(1).
22. 刘子晨,梁振. 2016竞争力: 医药上市公司研发投入10强榜. (2016-09-04)[2017-12-20] . http://www.phirda.com/newsinfo. aspx?id=15779.
23. 王蔚佳. 重大新药创制科技专项正式启动. 中国医药报, 2008-08-23(1).
24. 孙宇, 米献淼, 李鹏燕, 等. " 重大新药创制”重大专项: 中国药物创新体系建设与发展的新引擎. 中国新药杂志, 2013, 22(8): 868-872.
25. Lanthier M, Miller KL, Nardinelli C, et al. An improved approach to measuring drug innovation finds steady rates of first-in-class pharmaceuticals, 1987-2011. Health Aff (Millwood), 2013, 32(8): 1433-1439.

Previous Article
Better understanding and clinical application of immunonutrition
Next Article
无射线射频消融妊娠合并室性早搏一例

West China Medical Journal

Preliminary analysis on the establishment of drug innovation system and the innovation progress of Chinese pharmaceutical enterprises

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content